Artiva Biotherapeutics Inc. (ARTV)
ARTV trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1817241/000119312526100135/0001193125-26-100135-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | ARTV on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2024 |
| SEC CIK | 0001817241 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $0 |
| Net income | -$83.9M |
| Operating income | -$89.8M |
| Net margin | Needs revenue and net income |
| Operating margin | Operating income not reported |
| Revenue growth | -100.0% |
| Cash | $26.7M |
| Total assets | $130.9M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | Needs market cap and revenue |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-09 |
| Cash and burn | $61.2M cash; operating cash flow -$21.1M a quarter. | Report 2026-09-30 |
| Shares outstanding | 49,432,351 (2026-10-30); 24,544,904 a year earlier. | Cover page 2026-10-30 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the market | Latest 2026-05-08 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | KPMG LLP, San Diego, California, United States | PCAOB Form AP 2026-03-31 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $34.2M, sold $1.9M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | -$28.8M | -$28.4M | $61.2M | No debt tags | Needs four quarters | 10-Q 2026-11-09 |
| Q2 2026 2026-06-30 | Not filed | -$25.0M | -$20.4M | $301.5M | No debt tags | Needs four quarters | 10-Q 2026-11-09 |
| Q1 2026 2026-03-31 | Not filed | -$23.5M | -$20.9M | $21.0M | No debt tags | Needs four quarters | 10-Q 2026-11-09 |
| Q4 2025 2025-12-31 | Not filed | -$20.8M | -$14.7M | $26.7M | No debt tags | $0 | 10-K 2026-03-10 |
| Q3 2025 2025-09-30 | Not filed | -$21.5M | -$19.2M | $25.5M | No debt tags | Needs four quarters | 10-Q 2026-11-09 |
| Q2 2025 2025-06-30 | Not filed | -$21.3M | -$23.0M | $28.5M | No debt tags | Needs four quarters | 10-Q 2026-11-09 |
| Q1 2025 2025-03-31 | Not filed | -$20.3M | -$19.8M | $30.4M | No debt tags | Needs four quarters | 10-Q 2026-11-09 |
| Q4 2024 2024-12-31 | $0 | -$16.1M | -$14.7M | $40.2M | No debt tags | $251K | 10-K 2026-03-10 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3 | 2026-08-06 |
| Latest annual report | 10-K/A | 2026-04-30 |
| Latest quarterly / interim | 10-Q | 2026-11-09 |
| Latest current report | 8-K/A | 2026-11-09 |
| Latest proxy | DEF 14A | 2026-08-03 |
Source: SEC EDGAR submissions feed, 234 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -3.4% |
| 1 month | -36.2% |
| 3 months | -64.5% |
| Year to date | -6.5% |
| 1 year | +18.3% |
| From 52-week high | -70.1% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| CGEN | Compugen Ltd. | $2.04 | -2.86% | $193.0M |
| LCTX | Lineage Cell Therapeutics Inc. | $0.7951 | -13.07% | $201.1M |
| IKT | Inhibikase Therapeutics Inc. | $1.45 | -4.61% | $203.4M |
| PALI | Palisade Bio Inc. | $1.03 | -8.04% | $184.7M |
| CABA | Cabaletta Bio Inc. | $1.11 | -13.28% | $239.4M |
| IVVD | Invivyd Inc. | $0.5377 | -7.63% | $158.5M |
| IPHA | Innate Pharma S.A. ADS | $1.41 | -1.06% | $156.9M |
| STRO | Sutro Biopharma Inc. | $9.32 | -5.09% | $154.7M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier